A Cancer Trial's Unexpected Result: Remission in Every Patient
It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug. But the results were astonishing. The cancer vanished in every single patient, undetectable by physical exam; endoscopy; positron emission tomography, or PET scans; or MRI scans. Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by drug company GlaxoSmithKline, said he knnews.yahoo.com
CEO of Covid antibody maker Vir Biotech says their treatment 'stands up well' to all variants
A monoclonal antibody Covid treatment from Vir Biotechnology and GlaxoSmithKline "stands up well" to all variants of the virus, Vir President and CEO George Scangos told CNBC's "Power Lunch" on Wednesday. Scangos' comments came after the two companies announced contracts to sell $1 billion worth of their antibody, sotrovimab, to the U.S. government. The Food and Drug Administration granted sotrovimab an emergency use authorization in May to treat up to moderate Covid infections in adults and children. "It certainly is an effective antibody against Covid, but also against SARS, also against many other coronaviruses," Scangos said. "So not only, I think, do we have an antibody that stands up well to all the variants received from Covid, but potentially can help in future coronavirus pandemics as well."cnbc.com
GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug
GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug. The companies started testing the antibody on early-stage Covid patients in August, hoping to keep symptoms from progressing. Antibody drugs gained attention after they were used to treat former President Donald Trump last year. U.S. health officials say antibody drugs already authorized for use – from Regeneron and Eli Lilly – are being underutilized. GSK said the companies will also continue discussions with the European Medicines Agency and other global regulators to make the drug available to Covid patients as soon as possible.cnbc.com
Ex-US vaccine chief fired over sexual harassment allegations
FILE - In this Tuesday, Jan. 12, 2021 file photo, Dr. Moncef Slaoui, chief science adviser to Operation Warp Speed, the U.S. effort to rapidly develop COVID-19 vaccines, speaks during a news conference in Washington. On Wednesday, March 24, 2021, GlaxoSmithKline said Slaoui has been fired as chair of a medical research company over sexual harassment allegations. (AP Photo/Patrick Semansky, Pool)The former chief science adviser for the U.S. effort to rapidly develop COVID-19 vaccines has been fired from the board of directors of a medical research company over sexual harassment allegations, drugmaker GlaxoSmithKline said Wednesday. Slaoui served as chief science adviser to Operation Warp Speed, which was launched under the Trump administration to develop vaccines and treatments for COVID-19. GlaxoSmithKline said its investigation began after it received a letter in February outlining the allegations of “sexual harassment and inappropriate conduct."
Moncef Slaoui, ex-Operation Warp Speed science chief, fired from board over sexual harassment claim
Moncef Slaoui, the former scientific director of COVID-19 vaccine development at Operation Warp Speed during the Trump administration, has been fired from a joint venture of GlaxoSmithKline over allegations of sexual harassment, the drugmaker said Wednesday. GSK became aware of the claims against Slaoui in February and hired an outside law firm, Morgan Lewis, to investigate, the company announced. Slaoui is being ousted from his seat as chairman of the board of Galvani Bioelectronics, a joint venture between GSK and Verily Life Sciences. Appointed as scientific head of Operation Warp Speed last May, Slaoui left that role in January and briefly worked as an adviser to the Biden Administration. Slaoui worked for GSK from 2006 to 2017, overseeing research and development and later coronavirus vaccines.cbsnews.com
GSK fires ex-Operation Warp Speed chief Moncef Slaoui over 'substantiated' sexual harassment claims
Moncef Slaoui speaks with President Donald Trump about "Operation Warp Speed" in the Rose Garden at the White House on Friday, Nov 13, 2020 in Washington, DC. "Upon receipt of the letter, the GSK Board immediately initiated an investigation with an experienced law firm to investigate the allegations," GSK said. He is married to Kristen Slaoui, who previously served as vice president and head of business development at GSK. Slaoui also is chairman of the board of directors at the vaccine company Vaxcyte. Slaoui in January submitted his resignation as Operation Warp Speed chief advisor to the then-incoming administration of President Joe Biden.cnbc.com
UnitedHealth names former Glaxo CEO Witty to lead company
This photo provided by UnitedHealth Group shows Sir Andrew Witty. UnitedHealth Group is promoting former GlaxoSmithKline leader Sir Andrew Witty to become the health insurance providers next CEO immediately. (Richard Fleischman/UnitedHealth Group via AP)UnitedHealth Group is promoting former GlaxoSmithKline leader Sir Andrew Witty to become the health insurance provider’s next CEO immediately. UnitedHealth runs UnitedHealthcare, a health insurance business that covers more than 48 million people mostly in the United States. Shares of Minnetonka, Minnesota-based UnitedHealth Group Inc. slipped 2% to $330.41 while broader markets climbed in Thursday afternoon trading.
Big drugmakers just raised their prices on 500 prescription drugs
Drug prices are higher in the U.S. than in other developed countries, where governments typically negotiate with manufacturers to control costs. In a post on its website, 46brooklyn said it created the analysis to fight "the lack of transparency" in drug pricing, particularly in drugmaker Wholesale Acquisition Costs (WACs), which it sees as the root cause of the "American-made drug pricing crisis." President Trump signed executive orders earlier this year aimed at lowering drug prices. President-elect Joe Biden's health care platform has plans for combating rising drug prices, such as placing a cap on drug price increases and allowing Americans to buy prescriptions from other countries. In January 2019, drugmakers raised prices on 486 brand-name drugs by an average of 5.2% and, in January 2018, 580 brand-name drugs increased by an average of 8%.cbsnews.com
VIRUS TODAY: Health experts warn against holiday gatherings
With some Americans now paying the price for what they did over Thanksgiving, health officials are warning people begging them, even not to make the same mistake during the Christmas and New Year's season. Andrew Cuomo has ended indoor dining indefinitely in New York City as coronavirus cases and hospitalizations climb. As of Monday, only takeout orders and outdoor dining will be allowed in one of the world’s great cuisine capitals. THE NUMBERS: Deaths in the U.S. have climbed to almost 2,260 per day on average, about equal to the peak seen in mid-April. ___Find AP’s full coverage of the coronavirus pandemic at https://apnews.com/hub/coronavirus-pandemic
GSK, Sanofi say COVID-19 vaccine won't be ready until late 2021
Drugmakers GlaxoSmithKline and Sanofi say their potential COVID-19 vaccine won't be ready until late next year as they seek to improve the shot's effectiveness in older people. They said they now expect the vaccine to be available in the fourth quarter of 2021. GSK and Sanofi, based in London and Paris, respectively, said they were confident of the vaccine's ultimate success due to positive results from other tests. In adults ages 18 to 49, the vaccine produced an immune response comparable to patients who had recovered from COVID-19, the companies said. Separately, Pfizer's COVID-19 vaccine is likely to soon receive emergency use authorization from the Food and Drug Administration after a federal advisory panel on Thursday recommended the step.cbsnews.com
Sanofi, GSK say COVID-19 shot won't be ready until late 2021
LONDON – Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s effectiveness in older people. “The results of the study are not as we hoped,’’ Roger Connor, president of London-based GSK Vaccines, said in a statement. GSK and Sanofi plan to produce up to 1 billion doses of their COVID-19 vaccine annually, and they have signed agreements to supply millions of doses to the U.S., European Union, Canada and developing countries. The difficulties underscore the challenges scientists face as they race to develop COVID-19 vaccines, condensing a process that usually takes years into a matter of months. “We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine,” said Thomas Triomphe, head of Sanofi’s vaccine unit.
Top Biden advisor could face ethics pressure as his brother lobbies for pharma firms
Biden's campaign ran, in part, on the idea of reducing drug prices. Steve and Jeff Ricchetti co-founded their self-named lobbying shop over a decade ago. While Steve Ricchetti hasn't lobbied since before Biden became vice president, Jeff Ricchetti is still a registered lobbyist. Jeff Ricchetti lobbied the White House and other federal agencies when Biden was vice president, records show. During Biden's second term as vice president, Jeff Ricchetti had clients such as Eli Lilly, Sanofi and Boehringer-Ingelheim Pharmaceuticals.cnbc.com
Sanofi, GSK to provide 200 million Covid vaccine doses to WHO global immunization program
The deal is contingent on the vaccine winning regulatory approval, the companies said in a statement. "Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world," Roger Connor, president of GSK Vaccines, said in a statement. He added that "this has the potential to be a significant contribution to the global fight against COVID-19." The WHO has previously acknowledged that there won't be enough vaccine doses for everyone in the world once one candidate is authorized for use. "The more shots on goal we have, the higher the chances of having a very safe, very efficacious vaccine."cnbc.com
Pfizer tops 3Q earnings views, makes progress on COVID shot
Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus infections. Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience. It expects revenue of $48.8 billion to $49.5 billion, narrowed from its previous forecast of $48.6 billion to $50.6 billion. Pfizer will receive about $12 billion in return and its shareholders will get roughly one Viatris share for each Pfizer share they own. Pfizer expects to be able to grow revenue at least 6% annually through 2025 as a result of the transformation.
Antibody drugs are no cure but seem promising for COVID-19
But experimental antibody drugs like the one Trump was given are among the most promising therapies being tested for treating and preventing coronavirus infections. Eli Lilly and Regeneron Pharmaceuticals Inc. are asking the U.S. government to allow emergency use of their antibody drugs, which aim to help the immune system clear the virus. The company made a successful Ebola combo antibody treatment this way. A: Researchers are still trying to determine the best candidates for antibody treatment. About 5.8% of patients given placebo required hospitalization or an emergency room visit versus 0.9% of those given the antibodies.
The Latest: Honolulu to allow some activities to resume
(AP Photo/Audrey McAvoy)HONOLULU -- Honolulu Mayor Kirk Caldwell says the city plans to allow some activities that were shut down last month to control the spread of the coronavirus to resume under new guidelines. Gary Herbert will increase pandemic restrictions in two Utah cities as COVID-19 cases continue to surge in the state. The county accounted for 42% of the state’s cases despite having only 20% of state’s population. Eric Holcomb’s statewide mask mandate and other coronavirus restrictions poses a possible disruption to his reelection campaign. But the real toll is thought to be much higher, in part because many COVID-19 deaths were probably ascribed to other causes, especially early on, before widespread testing.
GlaxoSmithKline CEO calls coronavirus vaccine partnership with Sanofi an 'unprecedented collaboration'
GlaxoSmithKline CEO Emma Walmsley on Tuesday told CNBC's Jim Cramer that her company's newly announced partnership with industry peer Sanofi is an "unprecedented collaboration" between competitors. The European pharmaceutical giants are combining their resources to develop a Covid-19 vaccine and aim to produce a batch within the next 20 months. "But, a lot of work to do, and we're sure the world will need more than one vaccine, considering the state of demand." The two companies are "leaders who are both bringing proven pandemic technologies and scale to develop, hopefully, an adjutant vaccine against Covid-19," Walmsley said. "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone," Sanofi CEO Paul Hudson said in a statement.cnbc.com
Stocks making the biggest moves premarket: Morgan Stanley, Southwest, Tesla, Netflix & more
Southwest Airlines (LUV) Southwest took Boeing's (BA) grounded 737 Max jet off its flight schedule through June 6. XPO Logistics (XPO) XPO is considering a sale of the company or a spin-off of one or more business units. Tesla (TSLA) Tesla saw vehicle registrations in California cut nearly in half during the fourth quarter of 2019 compared to a year earlier. Netflix (NFLX) Netflix is collaborating with Ben & Jerry's on a new ice cream flavor called "Netflix & Chilll'd." PPG Industries (PPG) The paint maker missed estimates by 3 cents a share, with quarterly profit of $1.31 per share.cnbc.com